A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene

NCT00237185 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)

Interventions

DRUG: Imatinib mesylate

Sponsor

Novartis Pharmaceuticals